Nearly seven days after David Einhorn announced his short attack on Athenahealth, Inc (NASDAQ:ATHN), a Morgan Stanley report doesn’t mention the incident in its May 12 research note on the stock.
Athenahealth: Morgan “overweight,” notes potential for cost savings in sales, R&D
The report, which has Athenahealth, Inc (NASDAQ:ATHN) as an “overweight” in the portfolio, noted that “Steady state margins reflect the underlying earnings power of a mature company no longer investing in growth, characterized by lower R&D and sales & marketing spend.” Although the research note “do not expect it to reach maturity any time soon,” it did say that “hence our 2030 DCF horizon we think a good starting point to understand Athenahealth’s potential is to know where it is coming from.”
On May 8 ValueWalk had reported analysts with bull ratings on Athenahealth, Inc (NASDAQ:ATHN) are rushing to the company’s defense after David Einhorn’s very public short attack. Baird’s latest report defends athenahealth’s growth targets vehemently while reducing their price target to $175. The report explains that the change in PT has nothing to do with the short seller’s comments and is only based on industry multiples, which have compressed dramatically in the past months.
Morgan Stanley appears to be coming to the defense of Athena and its vivacious CEO John Bush, who called Athena “the greatest hope for our country.”
“I am absolutely sure Athenahealth, Inc (NASDAQ:ATHN) is a $1,000 per share stock,” Bush said as he boiled over with excitement on the CNBC set recently. “I have no idea when it gets there,” he later qualified, as the stock traded off its bubble high near $200 a share to exchange hands near $108 in early morning trading. “I don’t know anything about valuations, so for all I know (Einhorn) is right,” Bush later added.
Morgan Stanley notes stock with optimism
The Morgan Stanley report predicted it could reduce its sales force by 70%-85%, yet this stands in contrast to Bush, who said in the CNBC interview he was seeking to add head count in the sales department. “A closer look at R&D and sales & marketing highlights some margin expansion opportunity,” the report said. “Athenahealth, Inc (NASDAQ:ATHN) top line is growing ~30% with ~56% of reported R&D expense spent on growth initiatives and the remainder allocated towards maintenance/productivity enhancement.”
Where could they be wrong? Morgan Stanley points to a key issue, that “if maintenance R&D as a percent of revenues increases over time, Athenahealth, Inc (NASDAQ:ATHN) is unsuccessful in scaling its business or garnering incremental market share, Sales rep productivity decreases as growth matures, G&A & GM leverage not achieved with scale.”